Ramucirumab - Eli Lilly

Drug Profile

Ramucirumab - Eli Lilly

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Phase III Hepatocellular carcinoma; Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour
  • Phase I Solid tumours
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 10 Sep 2017 Efficacy and adverse event data from the phase III RANGE trial in Bladder cancer presented at the European Society for Medical Oncology 2017 Congress Presidential Symposium (ESMO-2017)
  • 01 Jul 2017 Eli Lilly completes a phase II trial in Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second line therapy or greater) in the USA and Canada (NCT01234402)
  • 31 May 2017 Adverse events data from the phase III RANGE trial in Urogenital cancer released by Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top